Global Dry Eye Syndrome Market Players Focus on Expanding Business in Fast-Growing Economies with New Product Launches 2021–2027 | Allergan, I-Med Pharma, Otsuka Pharmaceutical Co. Ltd., Allostera Pharma, and Acadia Pharmaceutical.

The latest research report on Dry Eye Syndrome market attempts to uncover the growth model of this domain during 2021-2027, in relation to the key growth drivers, challenges, as well the upcoming opportunities and associated risks. Moreover, it validates the values being presented by comparing the historical data and the current business landscape.

Get Sample Copy Of Keyword Market Research Report At: https://www.worldwidemarketreports.com/sample/493510

Dry eye syndrome is a common vision impairment, which is also known as keratoconjunctivitis sicca (KCS). Dry eye syndrome occurs when there is decreased tear production or less than adequate tear film lubrication on the surface of the eye. Although dry eye syndrome may occur in both women and men at any age, most frequently it affects women. Women suffer about twice the rate of dry eye syndrome in men.

The global dry eye syndrome market is divided into six regions, such as North America, South America, Asia Pacific, Europe, Middle East, and Africa.

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Dry Eye Syndrome market Size with a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Dry Eye Syndrome market.

Drivers:

Increasing incidence of dry eye syndrome and growing geriatric population around the world is expected to propel growth of the global dry eye syndrome market over the forecast period. For instance, according to American Association Ophthalmology, more than 344 million people worldwide (around 20 million people in the United States) have dry eye disease.

Moreover, the advancements in clinical trial for the rugs associated with dry eye syndrome and increasing research and development activities are expected to drive growth of the global dry eye syndrome market. For instance, in 2019, Santen Pharmaceutical and Oxford Biomedica entered into the research and development collaboration for the advancement of the gene therapy vectors for the inherited retinal diseases.

Restraint:

Lack of awareness among people about many dry eye symptoms and eye health is expected to impede growth of the global dry eye syndrome market.

Regional Insights:

North America is expected to witness significant growth in the global dry eye syndrome market due to increasing prevalence of dry eye disease (DED) and increasing demand for DED treatment in the region. Dry eyes are a common condition in the United States. For instance, in October 2019, Sun Pharmaceutical launched CEQUA for the treatment of dry eye syndrome in the United States. Moreover, CEQUA is approved by the Food and Drug Administration.

Major Points Covered in Table of Contents:

Dry Eye Syndrome Market Overview
Market Competition by Manufacturers
Production Market Share by Regions
Consumption by Regions
Global Dry Eye Syndrome Production, Revenue, Price Trend by Type
Global Dry Eye Syndrome Market Analysis by Applications
Company Profiles and Key Figures in Dry Eye Syndrome Business
Dry Eye Syndrome Manufacturing Cost Analysis
Marketing Channel, Distributors, and Customers
Market Dynamics
Global Dry Eye Syndrome Market Forecast
Research Findings and Conclusion
Methodology and Data Source

Buy Now: https://www.worldwidemarketreports.com/buy/493510

Competitive Section:

Key players involved in the global dry eye syndrome market are Novartis AG, Auven therapeutics, Novaliq GmBh, AFT pharmaceuticals, Santen Pharmaceuticals Co. Ltd., Johnson & Johnson Vision, Valent Pharmaceuticals, Allergan, I-Med Pharma, Otsuka Pharmaceutical Co. Ltd., Allostera Pharma, and Acadia Pharmaceutical.

In June 2019, Novartis acquired Xiidra from Takeda Pharmaceutical to boost their ophthalmic portfolio in the market.

In May 2019, Johnson & Johnson Vision showcased new eye care innovation and clinical data at the 2019 British Contact Lens Association Conference in the United Kingdom.

In December 2018, Alcon Inc. acquired Tear Film Innovations, Inc. to expand its product portfolio in ocular health products, as well as to expand its patient base by providing treatment for dry eye syndrome.

Contact Us:

Mr. Shah
Worldwide Market Reports,
Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737
Email: sales@worldwidemarketreports.com

About Us:
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

This release was published on openPR.